* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download View/Open - Minerva Access
Survey
Document related concepts
Complement system wikipedia , lookup
Lymphopoiesis wikipedia , lookup
Immunocontraception wikipedia , lookup
Immune system wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Duffy antigen system wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
DNA vaccination wikipedia , lookup
Gluten immunochemistry wikipedia , lookup
Innate immune system wikipedia , lookup
Adaptive immune system wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Adoptive cell transfer wikipedia , lookup
Transcript
For submission to International Journal of Peptide Research and Therapeutics Polymerisation of a T cell epitope with an immunostimulatory C3d peptide sequence enhances antigen specific T cell responses Neil M. O’Brien-Simpson, Troy J. Attard, Baihui Zheng, Katrina A. Walsh, Eric C. Reynolds* Oral Health CRC, Melbourne Dental School, Bio21 Institute, The University of Melbourne, 720 Swanston Street, Melbourne, Victoria, 3010, Australia. Running title: Enhancing peptide antigenicity *Corresponding author: Professor Eric C Reynolds, The University of Melbourne, Oral Health CRC, Melbourne Dental School, Bio21 Institute, 720 Swanston Street, Victoria 3010, Australia. Tel +61 3 9341 1447, Fax +61 3 9341 1599. Email: [email protected] Acknowledgements We also wish to thank Ms Jenny Davis for the animal welfare and handling. This work was supported by NHMRC grants: APP1029878 and APP1008106. 1 Abstract The complement protein C3d and C3d derived peptides that bind CD21 are known to enhance immunity to co-immunised antigens. In this study we have synthesised the minimal CD21 binding sequence of C3d (1227LYNVEA1232) as mono, di and tri tandem repeats and derivatised the N-terminus with an acryloyl moiety. These acryloyl-(C3d)n peptides were copolymerised with a acryloyl-T cell epitope (PAS1K) from the Porphyromonas gingivalis antigen the RgpA-Kgp proteinase-adhesin complex. The ability of C3d containing polymers to enhance T cell immunity in-vitro and in-vivo was evaluated. When used to stimulate invitro PAS1K-primed or RgpA-Kgp complex-primed T cells the C3d containing PAS1K polymers induced a mixed and significantly (p<0.05) higher IL-4 and IFNγ T cell response compared to that induced by the PAS1K peptide or polymer. PAS1K polymers containing tandem repeats of C3d induced a significantly (p<0.05) stronger maximal proliferative response, at the same antigenic dose, compared to that induced by the PAS1K peptide or polymer. When used as immunogens to prime T cells all of the C3d containing PAS1K polymers induced a dominant IFNγ T cell response and reduced the antigen dose required for maximal proliferation 150-fold compared to that required for the PAS1K- peptide or polymer primed T cells. In conclusion, the 6 residue sequence LYNVEA from C3d is sufficient to enhance immunity to an antigen and that the effect is more pronounced when C3d is part of the immunising antigen rather than an in-vitro stimulating antigen. Keywords: C3d complement; peptide synthesis; peptide polymers; T cell immune responses 2 Introduction Complement is typically regarded as a component of the innate immune system, however, degradation products particularly of the third complement factor, C3, are known to enhance the adaptive immune response to foreign antigens (Toapanta and Ross 2006). Activation of C3 leads to the generation of C3dg and its degradation product C3d which form covalent bonds with foreign antigens, thus providing a ligand for complement receptor 2 (CD21). CD21 is expressed on B cells, follicular dendritic cells (FDCs), epithelial cells and subsets of T cells (Hourcade et al. 1989). CD21 engagement with C3d is known to lower the antigen activation threshold in B cells and induce proliferation as well as playing a role in B cell memory and tolerance and immunoglobulin class switching (Fearon 1998; Frade et al. 1992; Mongini et al. 1997; Toapanta and Ross 2006). C3d-antigen complexes have been reported to enhance antigen processing and presentation by FDCs and they are retained on the cell surface for extended periods of time which has been shown to play a role in enhancing B cell activation, antibody production and memory (Bergmann-Leitner et al. 2006; Roozendaal and Carroll 2007; Zabel and Weis 2001). Although, CD21 is expressed on 1-23% of human and 4-5% of mouse T cells the functional role played by CD21 on T cells is yet to be fully elucidated (Levy et al. 1992; Molnar et al. 2008). However, CD21 expressing T cells have been shown to adhere strongly to C3d/CD21 bearing target cells and this enhanced binding is suggested to increase T cell activation and differentiation (Levy et al. 1992; Masilamani et al. 2002; Sinha et al. 1993). In mice, antigen immunisation has been shown to result in the increase in lymph node CD21+ T cells which is enhanced by the presence of C3d/CD21 bearing B cells (Kerekes et al. 1998; Molnar et al. 2008). C3d is a 35 kDa protein and although several binding sites for CD21 (CR2) have been postulated a 28 amino acid sequence (1209KFLTTAKDKNRWEDPGKQLYNVEATSYA1236) 3 was found to contain the minimal binding domain 1227LYNVEA1232 (Lambris et al. 1985). Dempsey et al. (1996) have shown that the fusion of C3d to a model antigen, hen egg lysozyme, enhanced the immune response to the antigen and that including 2 or 3 copies of C3d resulted in a 1,000 and 10,000 fold increase in the antibody response, respectively. Inclusion of multiple copies of C3d in either DNA, protein or polysaccharide based vaccines has been shown in several studies to enhance immunogenicity to the vaccine antigen, and a recent study suggests that 6 or more copies of C3d are necessary for efficient enhancement of the immune response (Green et al. 2003; Haas et al. 2004; Lou and Kohler 1998; Mitsuyoshi et al. 2005; Mkrtichyan et al. 2008; Suradhat et al. 2001; Toapanta and Ross 2006; Wang et al. 2006; Zhang et al. 2011). Although, the 28 amino acid C3d binding region peptide is known to have reduced affinity for CD21, its incorporation into a vaccine construct does enhance the immune response to the vaccine antigen and multiple copies of the peptide, up to three have been shown to induce stronger immunity and CD21 affinity than one or two copies of the peptide (Bergmann-Leitner et al. 2007; Bower and Ross 2006; Lou and Kohler 1998; Servis and Lambris 1989; Tsokos et al. 1990). Frade et al. (1992) have shown that a 16 residue synthetic peptide of C3d containing the minimal binding sequence 1227LYNVEA1232 does induce proliferation. In another study the multi-valency of a 13 residue C3d peptide (P13) containing the LYNVEA sequence was found to be essential for activation and proliferation as the multi-valent (four copies of P13) antigen was able to cross link CD21 bearing effector and target cells (Servis and Lambris 1989). In this study we investigated whether the minimal C3d binding sequence LYNVEA when polymerised with a T cell epitope from the oral bacterium Porphyromonas gingivalis is sufficient to enhance antigen specific T cell proliferative and cytokine responses. 4 Materials and Methods Chemicals and Reagents Unless stated otherwise, chemicals used for peptide-resin assembly were of peptide synthesis grade or its equivalent. O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBT), diisopropylethylamine (DIPEA), dimethylformamide (DMF), trifluoroacetic acid (TFA), piperidine, 9flourenylmethloxycarbonyl (Fmoc)-protected amino acids, Fmoc-6-amino hexanoic acid (Ahx) and Fmoc-L-Ala-WANG resin were purchased from Auspep Pty. Ltd., Melbourne, Australia while Fmoc-PAL-PEG-PS resin was purchased from PerSeptive Biosystems, Inc., Framingham, MA. Dichloromethane (DCM), diethyl ether, phenol, trishydroxymethylaminomethane (Tris), ethylenediamine tetraacetic acid (EDTA), methanol (MeOH) and ammonium chloride were purchased from Ajax Finechem, New South Wales, Australia. Acrylamide was obtained from BioRad Laboratories, New South Wales, Australia. Acryloyl chloride, acetonitrile, sodium bicarbonate, sodium hydroxide (NaOH) and sodium chloride (NaCl) were obtained from MERCK, Victoria, Australia. Triisopropylsilane (TIPS), guanidine-HCl, ammonium persulfate, tetramethylethylenediamine (TEMED), Dulbecco's phosphate buffered saline (PBS), complete Freund’s adjuvant (CFA), incomplete Freund’s adjuvant (IFA), Bovine Serum Albumin (BSA), L-glutamine, sodium pyruvate, gentamicin, penicillin, streptomycin, concanavalin A (ConA), N-lauroylsarcosine, and polyoxyethylene sorbitan monolaurate (Tween 20) were purchased from Sigma-Aldrich, New South Wales, Australia. Dulbecco's modified eagle's medium (DMEM) was obtained from SAFC Bioscience, Victoria, Australia. Fetal bovine serum (FBS) was purchased from GIBCO Invitrogen Corporation, Victoria, Australia. The antibodies (Abs) used in ELISPOT assay were bought from eBiosciences, San Diego, USA. 2-Mercaptoethanol and ammonium 5 bicarbonate were obtained from ICN Biomedicals, Inc., Costa Mesa, USA. 2,4,6Trinitrobenzene sulfonic acid (TNBSA) was kindly provided in powder form by Dr Denis Scanlon. Synthesis and purification of Acryloyl-Peptides All peptides were synthesised as acryloyl-Ahx-(Lys)4 derivatives and PAS1K (Acryloyl-Ahx(Lys)4-NYTAHGSETAWADPL, MW: 2311.6 Da) and C3d-based peptides, C3d (AcryloylAhx-(Lys)4-LYNVEA, MW: 1387.7 Da), [C3d]2 (Acryloyl-Ahx-(Lys)4-LYNVEALYNVEA, MW: 2077.5 Da) and [C3d]3 (Acryloyl-Ahx-(Lys)4-LYNVEALYNVEALYNVEA, MW: 2767.2 Da) were synthesized using the LibertyTM Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC, USA). Fmoc chemistry using Fmoc-protected amino acids and Fmoc-PAL-PEG-PS resin (0.20 mmol/g) or Fmoc-L-Ala-WANG (0.70 mmol/g) as the solid support was employed throughout the synthesis, with the completed peptides assembled as their C-terminal carboxyamide (PAS1K) or carboxyl forms (C3d-based peptides). FmocAhx-OH was manually coupled as a spacer (O'Brien-Simpson et al. 1997) to the N-terminus of each peptide via the addition of HBTU (5 equivalents), HOBT (5 equivalents) and DIPEA (9 equivalents) in DMF. Fmoc-Ahx-OH coupling was monitored by the TNBSA test (Hancock and Battersby 1976) and following a negative TNBSA test, the resin was washed with DMF (1 x 10 ml) and DCM (5 x 10 ml). Following removal of the Fmoc group [20% piperidine/DMF (v/v; 20 min) the peptide-resin was washed with DMF (6 x 5ml), DCM (6 x 5ml) and diethyl ether (6 x 5ml), then dried under reduced pressure (18h). Acryloylation of the dried Ahx-peptide-resins (0.1 mmol) were carried out manually using 8 fold molar excess of acryloyl chloride (0.8 mmol) and 16 fold molar excess of DIPEA (1.6 mmol) in anhydrous DMF (4 ml) under nitrogen for 1 hour and the reaction monitored using the TNBSA test. 6 The assembled acryloyl-Ahx-peptides were cleaved from the resin support and side chain deprotected using a mixture containing TFA/H2O/TIPS/phenol (92.5:2.5:2.5:2.5; v/v/v/v; 5 ml) for 2 hours. The TFA/peptide solution was collected by filtration and evaporated to approximately 1 mL under a stream of nitrogen at room temperature and the crude peptides precipitated in ice cold diethyl ether, centrifuged (4,000g), washed with diethyl ether (3 x 40ml) and dried under reduced pressure. The dried crude peptides were then dissolved in 0.1% (v/v) TFA in milliQ water and purified using a semi-preparative ZORBAX 300 SB-C18 column (9.4 mm x 25 cm) installed in a High Performance Liquid Chromatography (HPLC) 1100 system (Agilent Technologies Pty. Ltd., Victoria, Australia) under a flow rate of 4 ml/min using buffer A (0.1% v/v TFA in milliQ water) and buffer B (0.1% TFA in 90% acetonitrile, 10% milliQ water, v/v) as the limiting solvent. Peptide detection was performed by absorbance at 214 nm. Fractions were collected and identified using electrospray mass spectrometry (Esquire LC-MS, Bruker Daltonics, NSW, Australia). Polymerization of N-acryloyl-peptides N-acryloyl-Ahx-(Lys)4-PAS1K was polymerised singularly and with equimole equivalents of either N-acryloyl-Ahx-(Lys)4-C3d, N-acryloyl-Ahx-(Lys)4-[C3d]2 or N-acryloyl-Ahx-(Lys)4[C3d]3 in the presence of 50 mole equivalents of acrylamide as a co-monomer to produce the peptide polymers; poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2 and polyPAS1K+[C3d]3, respectively. Monomers (acryloyl-peptides and acrylamide) were dissolved in de-gassed polymerisation buffer (6 M guanidine-HCl containing 2 mM EDTA and 0.5 M Tris buffer, pH 8.) to yield a total monomer concentration of 2.5% w/v. Polymerization was initiated at room temperature and under nitrogen by the addition of 4% (w/w) ammonium 7 persulfate of the molar concentration of monomers present and 5 μL of a 20% v/v TEMED solution in polymerization buffer. After 18 hours the peptide polymers were dissolved in 50 mM ammonium bicarbonate and buffer exchanged using a Vivaspin 20 membrane column (GE Healthcare Life Sciences, NSW, Australia) at 8000 x g. The polymers were then purified via Gel Permeation Chromatography (GPC) using a Superdex 200 column (1.6 x 60 cm, GE Healthcare Life Sciences, NSW, Australia) installed in a 1100 HPLC system (Agilent Technologies Pty. Ltd., Victoria, Australia) with a flow rate of 0.5 ml/min, using an isocratic gradient of 50 mM ammonium bicarbonate as the running buffer. Detection was performed by UV absorbance at 214 nm. Isolated peptide polymers (>95% purity) were lyophilized using the Christ Freeze Dryer (Osterode am Harz, Germany) and stored at -20°C. Immunisation Protocols Animal experimentation was approved by the University of Melbourne animal ethics committee. For the T-cell activation studies, BALB/c mice were immunised with 60μg of acryloyl-Ahx-(Lys)4-PAS1K peptide or 50μg of RgpA-Kgp complex (prepared as described by Pathirana et al. (Pathirana et al. 2006) in complete Freund’s adjuvant (CFA) in the hock of the hind legs. In further experiments BALB/c mice were immunised with 50μg of peptide or peptide polymer antigens: acryloyl-Ahx-(Lys)4-PAS1K peptide, poly-PAS1K, polyPAS1K+C3d, poly-PAS1K+[C3d]2, poly-PAS1K+[C3d]3 in CFA. T-cell Proliferation Assays Seven days after immunisation lymphocytes were prepared from pooled inguinal and popliteal lymph nodes of BALB/c mice. Lymph nodes and spleens were collected in enriched Dulbecco’s Modified Eagles Medium/Ham’s Nutrient Mixture F12 (DMEM) 8 supplemented with 10% (v/v) heat inactivated (56ºC, 30 mins) foetal bovine serum (FBS), 2 mM glutamine, 2 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 30 μg/mL gentamicin, 100 I.U./mL penicillin and 100 μg/mL streptomycin (JRH Biosciences, Parkville, Australia), L-arginine (116 mg/mL), L-asparagine (36 mg/mL), and folic acid (6 mg/mL, Sigma, Melbourne, Australia) and single cell suspensions made by passing the lymph nodes or spleens through a wire mesh (200 μm). Red blood cells were removed from the spleen cell suspension by treatment with ammonium tris chloride buffer (17 mM Tris-HCl, 140 mM ammonium chloride in MilliQ water, pH 7.2) for five minutes at room temperature, and then washed three times in enriched DMEM (500 g, 5 mins at room temperature, IEC Centra GP8R refrigerated centrifuge, Thermo Electron Corporation, Melbourne, Victoria, Australia.). Monocytes and dead cells were removed from the lymph node cell suspension using Lympholyte®-M (Cedarlane® Laboratories Limited, Ontario, Canada) as per the manufacturers’ instructions. Lymph node T-cells were separated using mouse CD 90 (Thy1.2) magnetic micro beads (catalogue number 130-049-101, Miltenyi Biotech, Germany) and the AutoMACs (Miltenyi Biotech, Germany) as per the manufacturers’ instructions. Tcells were cultured in enriched DMEM at a concentration of 3 x 105 lymph node T-cells/well in a 96 well microtitre plate (Nunc, Denmark) in the presence of syngeneic γ-irradiated (2200 Rads) spleen cells (3 x 105cells/well) together with antigen: either acryloyl-Ahx-(Lys)4PAS1K peptide or polymer antigens, poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2, poly-PAS1K+[C3d]3 (concentration 80 – 0.04 nmol/mL) or RgpA-Kgp complex (concentration 25 – 0.01 μg/well) in a total volume of 250 μL. T-cells were incubated for four days at 37°C in an atmosphere of 5% CO2 in air. One μCi 3H-thymidine (Amersham Pharmacia Biotech, UK) was added per well in the final 18 hours of incubation. Cells were then lysed with cell lysis buffer (30 mM Tris-HCl, 100 mM EDTA, 1% N-Lauroylsarcosine, 9 pH 8) and harvested onto glass fibre filter mats using a Tomtec Harvester96® MACH III cell harvester (Tomtec, Connecticut, USA). The glass fibre filter mats were then air dried, and sealed in plastic bags containing 5 mL of Betaplate Scint (Perkin Elmer, N.S.W, Australia) and incorporation of 3H-thymidine was measured using a Wallac Microbeta Trilux Liquid Scintillation Counter (Perkin Elmer, N.S.W, Australia). Data is expressed as stimulatory index (S.I.) ± SD where S.I. is calculated as the counts per minute (cpm) divided by the negative control cpm and statistically analysed using one-way ANOVA and Dunnett’s 3T test (SPSS for Windows, Release 6.0; SPSS).. ELISPOT Assay ELISPOT assay was performed using the Millipore Multiscreen 96-well filtration plates (MAHAS450, Millipore, N.S.W, Australia). Plates were coated with anti-mouse cytokine capture antibodies (eBiosciences, San Diego, CA, USA), specific for IL-4 (catalogue number 14-7041, clone 11B11) and interferon-gamma (IFN-γ, catalogue number 14-7312, clone R46A2), at a concentration of 4 μg/mL in 0.1 M sodium bicarbonate buffer (pH 9.5) and incubated overnight at 4ºC. The ELISPOT plates were then washed with Dulbecco’s PBS and blocked with enriched DMEM for one hour at 37ºC. Lymph node T-cells and spleens were prepared as above. Antigen-primed lymph node cells (3 x 105/well) were incubated with γ-radiated (2200 Rads) syngeneic spleen cells as a source of APCs (3 x 105cells/well) and antigen: either RgpA-Kgp complex (5 μg/well) or acryloyl-Ahx-(Lys)4-PAS1K peptide or polymer antigens, poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2, poly-PAS1K+[C3d]3 (20 nmol/well). Plates were incubated at 37ºC in an atmosphere of 5% CO2 in air for 48 hours in a humidified incubator. The plates were then washed with phosphate buffered saline (PBS) containing 0.05% v/v Tween 20 (PBST) three times and once with MilliQ water. Cytokine-specific 10 biotinylated antibodies (eBiosciences, San Diego, CA, USA) specific for IL-4 (catalogue number 13-7042, clone BVD6-24G2) and IFN-γ (catalogue number 13-7311, clone XMG 1.2) were added at a concentration of 2 μg/mL in Dulbecco’s PBS/enriched DMEM (1:1, v/v) and incubated at room temperature for two hours. Plates were washed six times with PBST and Streptavidin-Alkaline Phosphatase conjugate (Roche, Germany) was added to the plates at a 1:1000 dilution in Dulbecco’s PBS/enriched DMEM (1:1, v/v) and incubated for one hour at room temperature. The plates were washed six times with PBST and three times with PBS, and 50 μL of substrate buffer (one tablet of 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium; BCIP/NBT, catalogue number B-565, Sigma-Aldrich, St Louis, MO, USA dissolved in 10 mL MilliQ water) was added per well. Spots were allowed to develop for 20 – 30 minutes, before stopping the reaction by washing with water. The spots were counted using EliSpot Reader Lite (version 2.9. Autoimmun Diagnostika GmbH Ebinger Strasse 4, Strassberg, Germany). Data is expressed as spot forming cells per million (SFC/million) and statistically analysed using one-way ANOVA and Dunnett’s 3T test (SPSS for Windows, Release 6.0; SPSS). 11 Results and Discussion Synthesis and polymerisation of peptide polymers To investigate the ability of the C3d minimal binding epitope LYNVEA (C3d) to act as a molecular adjuvant we initially synthesised via solid phase peptide chemistry using standard FMOC chemistry protocols the C3d peptide monomers as acryloyl-Ahx- derivatives. Based on the reports that multi-sequential copies of C3d enhance immunity, mono- di and trisequential LYNVEA repeats were produced. These acryloyl-Ahx-[C3d]n peptides although successfully synthesised were difficult to solubilise and the yield of purified peptides was less than 1 mg from a 0.1 mmole scale synthesis. To address the solubility issue the peptides were synthesised with a four lysine spacer between the acryloyl-Ahx moiety and the N-terminus of the [C3d]n peptide. The four lysine [(Lys)4)] spacer has been used in a number of studies to improve the solubility of peptides but also has an added benefit in that it functions as a cathepsin B cleavage site thus enhancing antigen processing at a site removed from the peptide epitope when it is incorporated into a macro-molecule (Rejmanova et al. 1983; Sarobe et al. 1993). With these features of the (Lys)4 motif in mind we synthesised the [C3d]n and PAS1K peptides as acryloyl-Ahx-(Lys)4 derivatives to enhance solubility and antigenicity, respectively. Furthermore, acryloyl-peptide monomers that are highly soluble in aqueous buffers were found to incorporate into polymers more readily (Jackson et al. 1997; O'Brien-Simpson et al. 1997). Figure 1A shows the HPLC chromatogram of the crude acryloyl-Ahx-(Lys)4-PAS1K (Ac-PAS1K) with the highlighted peak being the desired peptide and the inserted analytical HPLC chromatogram of the purified Ac-PAS1K (observed mass = 2312.7 Da, calculated mass = 2311.6 Da). The secondary product eluting earlier at 14.8 minutes was found to be a lysine deletion of Ac-PAS1K. The HPLC chromatogram of the crude acryloyl-Ahx-(Lys)4-[C3d]n (Ac-[C3d]n) peptide mixture for Ac-[C3d], Ac-[C3d]2 12 and Ac-[C3d]3 are shown in Figure 1B-D and clearly show one major synthetic product which corresponded to the desired peptide. For each sequential addition of C3d sequence (LYNVEA) there was an increase in the retention time of the peptide (Figure 1B-D) indicating an increasing hydrophobic nature of the minimal C3d binding sequence. The free radical polymerisation approach using ammonium persulphate and TEMED to initiate and activate co-polymerisation of the acryloyl-Ahx-(Lys)4-peptides and acrylamide was used and the reaction conditions were based on earlier reports (Jackson et al. 1997; O'Brien-Simpson et al. 1997). Similar to previous reports all of the peptide polymers eluted in the void volume of a size exclusion Superdex 200 column, which has an exclusion molecular weight of approximately 1.3 x 106 Da for globular structures (Figure 2A) (Jackson et al. 1997; O'Brien-Simpson et al. 1997). Amino acid analysis of the purified peptide polymers showed that the peptides contributed to 10-15% w/w of the polymers and the ratio of PAS1K to C3d peptide was similar to the peptide monomer ratio at the initiation of polymerisation (i.e 12.6% for Poly-PAS1K; 10.3% for Poly-PAS1K+[C3d] ratio 1:1.1; 14.7% for Poly-PAS1K+[C3d]2 ratio 1:0.9 and 12.8% for Poly-PAS1K+[C3d]3 ratio 1:0.9). These incorporation rates of peptides into acrylamide polymers are similar to those found by others {Jackson, 1997 #1231;O'Brien-Simpson, 1997 #1154}. Figure 2B shows a representative size exclusion profile of a PAS1K and [C3d]n co-polymer (PolyPAS1K+[C3d]n) eluting in the void volume (14.8 mins) and the unreacted monomers eluting in the inclusion volume (38-46 mins). Although all of the acryloyl-Ahx-(Lys)4-peptides could be polymerised with a small molecular weight co-monomer such as acrylamide none of the peptides formed polymers or oligomers in the abscence of a small molecular weight co-monomer as determined by size exclusion chromatography using Superdex 200 and Superdex-peptide columns to detect peptide polymers or oligomers, respectively (data not shown). Different acryloyl/vinyl 13 monomers are known to preferentially form block co-polymers (Sandler and Karo 1992) and steric hindrance is considered to be a major factor for monomers not forming single monomer species polymers. Each of the acryloyl-Ahx-(Lys)4-peptides eluted at high acetonitrile (buffer B) concentrations, indicating significant hydrophobicity (Figure 1). In the aqueous polymerisation buffer, this high level of hydrophobicity may result in increased steric hindrance about the acryloyl moiety, effectively suppressing free radical transfer in the polymerization reaction (Zou et al. 1993). As a consequence, each of the peptide polymers either containing a single peptide (PAS1K) or the heteropolymeric (PAS1K+[C3d]n) - are likely to be block co-polymers. T cell proliferative and cytokine responses induced by the peptide polymers A number of studies have shown that incorporation of C3d tandem repeats of either the whole protein sequence or peptides incorporating the CD21 binding site sequence into DNA-, recombinant protein-, or peptide- based immunogens enhances immunity to the coimmunised antigen (Bergmann-Leitner et al. 2007; Bower and Ross 2006; Lou and Kohler 1998; Servis and Lambris 1989; Tsokos et al. 1990; Zhang et al. 2011). Furthermore, Servis and Lambris (1989) have shown that four copies of a 13 residue C3d peptide pendent from εamino groups of lysine residues in a linear peptide template was sufficient to enhance T cell proliferation by cross-linking the CD21 receptor on the T cell and the antigen presenting cell. Free radical polymerisation of the minimal CD21 binding sequence LYNVEA from C3d and tandem repeats of it would incorporate into one immunogen both valency features known to enhance immunity. Using the PAS1K+[C3d]n polymers we were able to investigate whether; the minimal CD21 binding sequence is sufficient to enhance immunity and if copy number or tandem repeats of LYNVEA induce a larger effect. 14 To investigate whether the peptide polymers would enhance antigen specific T cell responses, mice were immunised with either the PAS1K peptide or the native antigen the RgpA-Kgp complex and after 7 days the isolated lymph node T cells were stimulated in-vitro with peptide and peptide polymers. Figure 3 shows the T cell proliferative responses of antigen primed and antigen stimulated T cells with the typical proliferative profiles of a maximal stimulation at a certain antigen concentration followed by inhibition of T cell stimulation at higher antigen doses via anergy and/or apoptosis {Falk, 2000 #8519;LaSalle, 1994 #8520}. Figure 3A shows that PAS1K peptide primed T cells when incubated with PAS1K peptide had a maximal proliferative response at an antigen concentration of 40 nmol. Similarly, Poly-PAS1K+[C3d]2 and Poly-PAS1K+[C3d]3 both induced a maximal T cell response at an antigen concentration of 40 nmol, with Poly-PAS1K+[C3d]2 inducing a significantly (p<0.05) stronger T cell response compared to PAS1K peptide and PolyPAS1K+[C3d]3 stimulated T cells. Interestingly, Poly-PAS1K and Poly-PAS1K+[C3d] did not induce a T cell response in the PAS1K primed T cells. For RgpA-Kgp complex primed T cells Poly-PAS1K+[C3d]2 and Poly-PAS1K+[C3d]3 both induced a significantly (p<0.05) stronger T cell response compared to that induced by the PAS1K peptide (Figure 3B). Although Poly-PAS1K did not induce a T cell response in the RgpA-Kgp complex primed T cells, Poly-PAS1K+[C3d] induce a T cell response at an antigen concentration of 20 nmol, albeit, significantly (p<0.05) weaker than that induced by the other stimulating antigens. The lack of stimulation of T cells with Poly-PAS1K and Poly-PAS1K+[C3d] may be due to antigen processing of the PAS1K peptide from the polymer back bone, resulting in the cleavage of the PAS1K peptide within the T cell epitope, thus reducing the amount of antigen available. Several studies have shown that conjugation of a T cell epitope into a construct reduces T cell stimulation as the epitope in the peptide construct is enzymatically hydroysed during antigen processing, not necessary for free peptide, which reduces the amount of 15 stimulatory peptide presented via MHC class II to T cells {Dyrberg, 1986 #8515;Fitzmaurice, 2000 #8518;Lu, 1991 #8516;Partidos, 1992 #8517}. The C3d tandem repeat peptide polymers Poly-PAS1K+[C3d]2 and Poly-PAS1K+[C3d]3 both induced a strong proliferative response. Several studies have shown that tandem repeats of C3d peptides enhances immunity to the co-immunised antigen by lowering the antigenic stimulation threshold (Bower and Ross 2006; Haas et al. 2004; Servis and Lambris 1989; Zhang et al. 2011). Assuming that PAS1K is processed in a similar way for all of the peptide polymers, the inclusion of at least two tandem repeats of the minimal C3d sequence LYNVEA into the peptide polymers rather than a single copy were sufficient to reduce the antigenic threshold so that the available peptide (PAS1K) was more efficient at stimulating a T cell proliferative response. To investigate whether the C3d peptide polymers could enhance immunity in-vivo, mice were immunised with each peptide polymer and the PAS1K peptide and the ability of the antigen primed T cells to proliferate was evaluated using the native antigen the RgpAKgp complex in-vitro. Figure 3C shows that the PAS1K peptide and Poly-PAS1K primed T cells had maximal proliferative responses at 3.13 and 1.56 μg/well of RgpA-Kgp complex, respectively and that the PAS1K peptide primed T cells had a significantly (p<0.01) stronger response compared to Poly-PAS1K primed T cells. All of the PAS1K+C3d peptide polymer primed T cells had maximal proliferative responses at a stimulating antigen concentration of 0.02 μg/well which was significantly (p<0.05) lower concentration than that of the maximal proliferative response by the PAS1K peptide or Poly-PAS1K-primed T cells. Furthermore, the total T cell numbers isolated from the PAS1K+C3d peptide polymer immunised mice was consistently 10% higher in each experiment compared to T cell numbers isolated from PAS1K peptide and Poly-PAS1K immunised mice. 16 The ability of C3d containing peptide polymers to enhance immunity to a far greater extent in-vivo than in-vitro may be due to the immunostimulatory effects of C3d on the antigen presenting cells. CD21 the receptor for C3d is known to be up regulated on APCs upon activation, thus enhancing cross-linking of APC’s and T cells via CD21/C3d ligation and reducing the T cell activation threshold (Allison 1998). This would result in an increase of the polydiversity of the antigen specific T cell repertoire and their proportion within the whole T cell population. APC’s in in-vitro assays are treated chemically or with radiation to prevent them from proliferating and generating proteins. Thus, unlike in-vivo-APC’s, invitro-APC’s would not be able to up regulate CD21 on their surface, which may account for why the C3d containing peptide polymers were able to enhance a stronger immune response when used to immunise rather than stimulate. To further investigate the effects of the C3d containing peptide polymers, T cells isolated from antigen primed mice were stimulated with antigen in-vitro and the IFNγ and IL4 cytokines secreted were analysed by ELISPOT (Figure 4). PAS1K peptide and PolyPAS1K+[C3d]3 induced a mixed IL-4 and IFNγ response in PAS1K-primed T cells, whereas Poly-PAS1K+[C3d] and Poly-PAS1K+[C3d]2 induced a significantly (p<0.05) stronger IL-4 response (Figure 4A). In RgpA-Kgp complex primed T cells the PAS1K peptide stimulated a mixed IL-4 and IFNγ response (Figure 4B). Poly-PAS1K induced a significantly (p<0.05) weaker IL-4 and IFNγ response compared to that induced by the other peptide polymers or PAS1K peptide. All of the PAS1K+C3d containing polymers induced a mixed IL-4 and IFNγ response which was significantly (p<0.05) stronger than the response induced by the PAS1K peptide with the RgpA-Kgp complex-primed T cells (Figure 4B). Figure 4C shows the IL-4 and IFNγ response induced by the RgpA-Kgp complex on PAS1K peptide and peptide polymer primed T cells. The RgpA-Kgp complex induced a mixed IL-4 and IFNγ response in PAS1K primed T cells, whereas Poly-PAS1K primed T cells had a predominant IL-4 17 cytokine response. In contrast, all of the Poly-PAS1K+[C3d]n primed T cells had a predominantly and significantly (p<0.05) higher IFNγ response compared to the response of PAS1K peptide or Poly-PAS1K primed T cells, indicating that C3d may promote a Th1 cell phenotype. C3d is known to promote and enhance both IL-4 and IFNγ responses and is regarded as a general immunostimulatory agent (Bower and Ross 2006). However, Wang et al. (2006) and Suradhat et al. (2001) reported that incorporation of multiple repeats of C3d molecules into DNA based vaccines resulted in a predominant Th2 phenotype. Alternatively, Allison (1998) and Knopf et al. (2008) demonstrated that immunising with tandem repeats of C3d sequences in recombinant protein and peptide based vaccines induced a Th1 cell phenotype. Furthermore, peptides containing the LYNVEA C3d sequence have been shown to directly interact with the T cell receptor inducing secretion of IFNγ from T cells (Knopf et al. 2008). When used as stimulating antigens in-vitro, C3d containing peptide polymers tend to promote a mixed Th1/Th2 response indicating a general immunostimulatory role of C3d in the polymers. When used as immunising antigens, however, there is a strong promotion of a Th1 phenotype, which is consistent with the response when immunising with protein/peptide based vaccines containing C3d sequences (Allison 1998; Knopf et al. 2008). The ability of Poly-PAS1K and Poly-PAS1K+C3d to induce cytokine secretion in PAS1K primed and RgpA-Kgp complex primed T cells, while inducing weak or undectable proliferation, could be attributed to the incubation time and level of sensitivity of each assay. For certain antigens ELISPOT assays have been shown to be more sensitive compared to a 3H-thymidine assay and at the point when 3H-thymidine is added to detect proliferation, the response induced by weakly stimulating antigens is typically poorly detected (Macatangay et al. 2010; Schultes and Whiteside 2003; Troye-Blomberg et al. 1984). Furthermore, T cell cytokine secretion can also be independent of proliferation (Jung et al. 1999). These may in part 18 explain the differences in the cytokine and proliferative responses induced when PolyPAS1K and Poly-PAS1K+C3d are used as stimulating antigens in-vitro. According to the results presented here, however, peptide polymers used to immunise mice promoted strong T cell proliferative and cytokine secretion responses. When used to immunise mice PolyPAS1K induced a weaker proliferative response than peptide alone indicating that the PAS1K T cell epitope may not be as biologically available as PAS1K peptide. The reduced stimulation of T cells by the inclusion of PAS1K into a polymer was overcome by inclusion of monomeric or tandem repeats of the C3d sequence LYNVEA, which improved the magnitude of the T cell response and reduced the activation threshold compared to that induced by peptide polymer without C3d. 19 Concluding Remarks In conclusion, we have demonstrated that acryloyl-peptides and acryloyl-derivatised immuno-stimulatory C3d peptide, can be co-polymerised to yield high molecular weight antigens. We have shown that valency of C3d in terms of tandem repeats but also copy number in a peptide polymer is important to enhance the immune response to the coimmunised antigen. Previous studies have included the minimal CD21 binding domain of C3d (LYNVEA) as part of a larger sequence, however, our data has shown that incorporation of just the minimal C3d binding residues is sufficient to enhance immunity and that the effect is more pronounced when C3d is part of the immunising antigen rather than an in-vitro stimulating antigen. Our finding that the 6 residue sequence LYNVEA from C3d is sufficient to enhance immunity to a co-immunised antigen may further the adoption of C3d as an immunostimulatory component in vaccine formulations. 20 References Allison AC (1998) The mode of action of immunological adjuvants. Dev Biol Stand 92: 3-11. Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC (2007) C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine 25: 7732-7736. Bergmann-Leitner ES, Leitner WW, Tsokos GC (2006) Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol 121: 177-185. Bower JF, Ross TM (2006) A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol 586: 249-264. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350. Fearon DT (1998) The complement system and adaptive immunity. Semin Immunol 10: 355361. Frade R, Hermann J, Barel M (1992) A 16 amino acid synthetic peptide derived from human C3d triggers proliferation and specific tyrosine phosphorylation of transformed CR2positive human lymphocytes and of normal resting B lymphocytes. Biochem Biophys Res Commun 188: 833-842. Green TD, Montefiori DC, Ross TM (2003) Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77: 2046-2055. 21 Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, Bower JF, Ross TM, Tedder TF (2004) Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol 172: 5833-5837. Hancock WS, Battersby JE (1976) A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzene-sulphonic acid. Anal Biochem 71: 260. Hourcade D, Holers VM, Atkinson JP (1989) The regulators of complement activation (RCA) gene cluster. Adv Immunol 45: 381-416. Jackson DC, O' Brien-Simpson N, Ede NJ, Brown LE (1997) Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 15: 16971705. Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R, Schraut W, Gruner N, Zachoval R, Hoffmann R, Santantonio T, Wachtler M, Pape GR (1999) Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261: 165-172. Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A (1998) A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol 10: 1923-1930. Knopf PM, Rivera DS, Hai SH, Mcmurry J, Martin W, De Groot AS (2008) Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol 86: 221225. Lambris JD, Ganu VS, Hirani S, Muller-Eberhard HJ (1985) Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A 82: 4235-4239. 22 Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM (1992) T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 90: 235-244. Lou D, Kohler H (1998) Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat Biotechnol 16: 458-462. Macatangay BJ, Zheng L, Rinaldo CR, Landay AL, Pollard RB, Pahwa S, Lederman MM, Bucy RP (2010) Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol 17: 1452-1459. Masilamani M, Von Seydlitz E, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206: 528-536. Mitsuyoshi JK, Hu Y, Test ST (2005) Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide. Infect Immun 73: 7311-7316. Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, Yu J, Glenn GM, Ross TM, Agadjanyan MG, Cribbs DH (2008) Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol 27: 19-24. Molnar E, Prechl J, Erdei A (2008) Novel roles for murine complement receptors type 1 and 2 II. Expression and function of CR1/2 on murine mesenteric lymph node T cells. Immunol Lett 116: 163-167. 23 Mongini PK, Vilensky MA, Highet PF, Inman JK (1997) The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 159: 3782-3791. O'brien-Simpson N, Ede NJ, Brown LE, Swan J, Jackson DC (1997) Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines. J Am Chem Soc 119: 1183. Pathirana RD, O'brien-Simpson NM, Veith PD, Riley PF, Reynolds EC (2006) Characterization of proteinase-adhesin complexes of Porphyromonas gingivalis. Microbiology 152: 2381-2394. Rejmanova P, Kopecek J, Pohl J, Baudys M, Kostka V (1983) Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B†‡. Makromolekule Chemie 184: 2009. Roozendaal R, Carroll MC (2007) Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 219: 157-166. Sandler SR, Karo W (1992) Polymer Synthesis, Boston, Academic Press. Sarobe P, Lasarte JJ, Larrea E, Golvano JJ, Prieto I, Gullon A, Prieto J, Borras-Cuesta F (1993) Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells. Res Immunol 144: 257-262. Schultes BC, Whiteside TL (2003) Monitoring of immune responses to CA125 with an IFNgamma ELISPOT assay. J Immunol Methods 279: 1-15. Servis C, Lambris JD (1989) C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. J Immunol 142: 2207-2212. 24 Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD (1993) Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript. J Immunol 150: 5311-5320. Suradhat S, Braun RP, Lewis PJ, Babiuk LA, Van Drunen Littel-Van Den Hurk S, Griebel PJ, Baca-Estrada ME (2001) Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 83: 79-92. Toapanta FR, Ross TM (2006) Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36: 197-210. Troye-Blomberg M, Romero P, Patarroyo ME, Bjorkman A, Perlmann P (1984) Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol 58: 380-387. Tsokos GC, Lambris JD, Finkelman FD, Anastassiou ED, June CH (1990) Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Iginduced human B cell intracytoplasmic free calcium concentration. J Immunol 144: 1640-1645. Wang XL, Zhao XR, Yu M, Yuan MM, Yao XY, Li DJ (2006) Gene conjugation of molecular adjuvant C3d3 to hCGbeta increased the anti-hCGbeta Th2 and humoral immune response in DNA immunization. J Gene Med 8: 498-505. Zabel MD, Weis JH (2001) Cell-specific regulation of the CD21 gene. Int Immunopharmacol 1: 483-493. 25 Zhang D, Xia Q, Wu J, Liu D, Wang X, Niu Z (2011) Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d-p28 and GP5 gene of porcine reproductive and respiratory syndrome virus. Vaccine 29: 629-635. Zou Y, Lin J, Dai L, Pan R (1993) Gaodeng Xuexiao Huaxue Xuebao 14: 294. 26 Figure Legends Figure 1: Analytical Reverse phase-HPLC profiles of synthetic acryloyl-peptides. Reversed phase HPLC (RP-HPLC) profile of crude acryloyl-peptides with the corresponding analytical RPHPLC of the purified acryloyl-peptide and ES-MS observed mass (insert) of; (A) acryloylPAS1K, expected molecular weight [m/z 2312.6 (M+H)+], (B) acryloyl-C3d, expected molecular weight [m/z 1388.7 (M+H)+], (C) acryloyl-[C3d]2, expected molecular weight [m/z 2078.5 (M+H)+], and (D) acryloyl-[C3d]3, expected molecular weight m/z 2768.2 (M+H)+]. RP-HPLC was performed using a semi-preparative Zorbax 300 SB-C18 column installed in a HPLC system. Peptide separation was achieved using 0-100% buffer B (0.1% TFA in 90% acetonitrile, 10% milliQ water, v/v) gradient over a period of 30 min at a flow rate of 4.0 ml/min. Figure 2: Size exclusion chromatography profiles of crude synthetic polymers. (A) Size exclusion chromatography profile of Poly-PAS1K. Elution times of the standards, Thyroglobulin (A, MW: 669kDa), Ferritin (B, MW: 440kDa) and Catalase (C, MW: 232kDa) are indicated by vertical arrows. (B) Size exclusion chromatography profile of PolyPAS1K+[C3d]3, collected from time 15.0-17.0 min as indicated by the vertical lines. Size exclusion chromatography was performed using a Superdex 200 column installed in a HPLC system. Separation was based on molecular size using an isocratic gradient of 50 mM ammonium bicarbonate as the running buffer at a flow rate of 0.5 ml/min. Detection was performed by absorbance at 214 nm. 27 Figure 3: T-cell proliferative responses induced by peptide polymers. T-cells were isolated from the popilteal and inguinal lymph nodes of BALB/c seven days after immunisation with antigen (peptide, peptide-polymer or the RgpA-Kgp complex) and then re-stimulated in-vitro to determine T cell proliferative response. T-cells were isolated from PAS1K peptide (A) and RgpA-Kgp complex (B) immunised mice and were incubated with γirradiated syngeneic spleen cells and either PAS1K peptide () or peptide polymer; PolyPAS1K (), Poly-PAS1K+C3d (), Poly-PAS1K+[C3d]2 () or Poly-PAS1K+[C3d]3 (), concentration of the stimulating antigen was based on PAS1K. (C), T-cells isolated from antigen (PAS1K peptide () or peptide polymer; Poly-PAS1K (), Poly-PAS1K+C3d (), Poly-PAS1K+[C3d]2 () or Poly-PAS1K+[C3d]3 ()) immunised mice and were incubated with γ-irradiated syngeneic spleen cells and the native antigen the RgpA-Kgp complex. T-cell proliferation was measured using 3H-thymidine incorporation for the last 18 hours of the assay and is expressed as the stimulatory index (S.I.). Data is representative of duplicate assays ± SD. Figure 4: T-cell cytokine responses induced by peptide polymers. T-cells were isolated from the popilteal and inguinal lymph nodes of BALB/c seven days after immunisation with antigen (peptide, peptide-polymer or the RgpA-Kgp complex) and then re-stimulated in-vitro to determine the antigen-specific IL-4 and IFNγ secretion response. T-cells were isolated from the PAS1K peptide (A) and RgpA-Kgp complex (B) immunised mice and were incubated with γ-irradiated syngeneic spleen cells and either PAS1K peptide or peptide polymer (Poly-PAS1K, Poly-PAS1K+C3d, Poly-PAS1K+[C3d]2 or Poly-PAS1K+[C3d]3), concentration of the stimulating antigen was based on PAS1K. (C), T-cells isolated from antigen (PAS1K peptide or peptide polymer; Poly-PAS1K, Poly-PAS1K+C3d, PolyPAS1K+[C3d]2 or Poly-PAS1K+[C3d]3 immunised mice and were incubated with γ- 28 irradiated syngeneic spleen cells and the native antigen the RgpA-Kgp complex. IL-4 and IFNγ T-cell cytokine responses were determined after 2 days of incubation. Data is expressed as spot forming cells per million (SFC) ± SD minus the background, and is representative of triplicate or duplicate assays. 29